Draft - May 12, 2021

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30329 May 12, 2021

Dr. Heather Scobie (CDC/CGH)

AGENDA ITEM	PRESIDER/PRESENTER(s)
-------------	-----------------------

Wednesday, May 12, 2021		
11:00	Welcome & Introductions	Dr. José Romero (ACIP Chair)
		Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
11:30	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Safety, immunogenicity and efficacy of BNT162b2 in persons aged 12-15 years	Dr. John Perez (Pfizer)
	GRADE: Pfizer-BioNTech COVID-19 vaccine	Dr. Megan Wallace (CDC/NCIRD)
	Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 vaccine	Dr. Sara Oliver (CDC/NCIRD)
	Clinical considerations and implementation: Adolescent COVID-19 vaccines	Dr. Kate Woodworth (CDC/NCBDDD)
1:30	Break	
2:00	Public Comment	
2:30	Break	
2:45	Discussion	
	<u>VOTE</u>	
	Pfizer COVID-19 Vaccine for 12-15 year olds	Dr. Sara Oliver (CDC/NCIRD)
3:30	Break	
3:45	Update on thrombosis with thrombocytopenia syndrome (TTS) following Janssen	Dr. Tom Shimabukuro (CDC/NCEZID)
	COVID-19 vaccine	
	VaST update	Dr. Grace Lee (ACIP, VaST Chair)
	COVID-19 Vaccine Effectiveness studies	Dr. Katherine Fleming-Dutra (CDC/NCIRD)

Acronyms

5:00

CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services

Update on emerging SARS-CoV-2 variants

COVID-19 Coronavirus disease 2019

Adjourn

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization VE Vaccine Effectiveness